Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
Johnson & Johnson has indicated that its acute myeloid leukemia (AML) drug, JNJ-63709178, has been put on clinical hold because of serious side effects.
Japan’s Astellas Pharma Inc. and San Diego-based Vical Inc. said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.
A global fund has raised over $12.9 billion from international donors as part of a campaign aimed at effectively eradicating AIDS, malaria and tuberculosis by 2030, conference organizers said.
Novartis’ investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said, citing a new analysis of a late-stage trial.
Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.
The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported.
Brain cancer is now the deadliest form of childhood cancer in the United States, surpassing leukemia as treatment advances have allowed doctors to cure many blood-related cancers, the Centers for Disease Control and Prevention said.
U.S. drugmaker Pfizer Inc.’s breast cancer drug Ibrance should be given marketing approval, an advisory committee at the European Medicines Agency recommended.